HALOZYME THERAPEUTICS, INC.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $9.44 | $9.55 | $9.37 | $9.51 | 27.80M |
| Jul 2, 2026 | $9.79 | $9.89 | $9.35 | $9.44 | 24.07M |
| Jul 1, 2026 | $9.68 | $9.97 | $9.58 | $9.79 | 23.09M |
| Jun 30, 2026 | $9.56 | $9.72 | $9.46 | $9.68 | 30.68M |
| Jun 29, 2026 | $9.32 | $9.80 | $9.11 | $9.56 | 36.68M |
| Jun 28, 2026 | $9.31 | $9.35 | $9.30 | $9.32 | 23.29M |
| Jun 27, 2026 | $9.25 | $9.38 | $9.22 | $9.31 | 25.32M |
| Jun 26, 2026 | $9.25 | $9.29 | $9.19 | $9.25 | 37.77M |
Company Overview
HALOZYME THERAPEUTICS, INC. operates in the technology space within the Technology sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 14 · Independent 11 of 14| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 20 | Truist Financial | $15.12 | Neutral |
| Jun 19 | Citi | — | Strong Buy |
| Jun 17 | BofA Securities | $10.95 | Hold |
| Jun 7 | Piper Sandler | $11.83 | Strong Buy |
| Jun 6 | Tigress Financial | $9.56 | Overweight |
| May 21 | Rosenblatt | $12.01 | Buy |
Politician Trades
View allWhat's Happening Right Now
- Sep 18, 2026 · Financing ↗ — Halozyme priced an upsized $1.3 billion offering of 1.50% convertible senior notes due 2033.
- Sep 16, 2026 · Financing ↗ — The company had initially announced a proposed $1.05 billion convertible senior notes offering due 2033 before it was upsized.
- Sep 11, 2026 · Earnings ↗ — Shares were boosted following reports of record revenue growth.
- Sep 12, 2026 · Insider Activity ↗ — Halozyme's CEO exercised options and sold 60,000 shares.
- Sep 18, 2026 · Insider Activity ↗ — A company director sold 18,996 shares of Halozyme stock.
Snapshot
Halozyme generated $1.40 billion in revenue for FY2025, up 37.6% year-over-year, with net income of $316.89 million representing a 22.7% margin. Operating income reached $469.01 million, while R&D spending was relatively modest at $81.49 million, or 6% of revenue. The company produced strong operating cash flow of $651.56 million against minimal capital expenditures of $6.97 million, yielding free cash flow of $644.59 million. However, the balance sheet shows only $133.82 million in cash against total debt of $2.14 billion, a gap the company is addressing via a newly priced $1.3 billion convertible notes offering due 2033.
Bottom Line
Halozyme combines high-margin, fast-growing royalty-based revenue with strong free cash flow generation, reflecting an efficient, low-R&D business model. However, the company carries substantial leverage relative to its cash position, and it just added $1.3 billion in new convertible debt, raising questions about capital allocation even as insiders including the CEO have been selling shares. The core tradeoff is strong profitability and cash generation versus rising debt levels and insider selling amid a well-priced growth narrative.